Postprandial glycemia - Review of current pathophysioogical, epidemiological and clinical aspects;Glikemia poposiłkowa - Przegla̧d zagadnień patofizjologicznych, epidemiologicznych i klinicznych

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 5-6, 2007, Pages 252-259

  Strojek, Krzysztof ^a   Majkowska, Liliana ^b   Zozulińska, Dorota ^c   Gumprecht, Janusz ^a   Krzymień, Janusz ^d   Małecki, Maciej ^e  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d Warszawskiego Uniwersytetu Medycznego   (Poland)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Complications; Diabetes; Postprandial glycaemia

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CLINICAL FEATURE; CLINICAL PRACTICE; CORRELATION ANALYSIS; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT MONITORING; PREVALENCE; REVIEW; SURVIVAL RATE; VASCULAR DISEASE; BLOOD; POSTPRANDIAL STATE;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; POSTPRANDIAL PERIOD;

EID: 34848834192     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.146     Document Type: Review

References (43)

1. 1c. Diabetes Care. 2003; 26: 881-885.
2. Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow up of the Belfast Diet Study. Diabet Med. 1998; 15: 290-296.
3. UKPDS Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care. 1998; 21:87-92.
4. Coates PA, Ollerton RL, Luzio SD, et al. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract. 1994; 26:177-187.
5. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988; 318: 1231-1239.
6. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002; 346:802-810.
7. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29: 46-52.
8. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003; 52: 102-110.
9. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007; 28: 187-218.
10. Heine RJ, Balkau B, Ceriello A, et al. What does postprandial hyperglycaemia mean? Diabet Med. 2004; 21: 208-213.
11. Daugherty KK. Review of Insulin Therapy. J Pharm Pract. 2004; 17: 10-19.
12. Zimmerman BR. Postprandial hyperglycemia: Implications for practice. Am J Cardiol. 2001; 88: 32H-36H.
13. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54: 1615-1625.
14. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med. 1998; 15: 188-193.
15. Ceriello A, Bortolotti N, Motz E, et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism. 1999; 48: 1503-1508.
16. Zozulinska DA, Wierusz-Wysocka B, Wysocki H, et al. The influence of insulin-dependent diabetes mellitus (IDDM) duration on superoxide anion and hydrogen peroxide production by polymorphonuclear neutrophils. Diabetes Res Clin Pract. 1996; 33: 139-144.
17. Pisarczyk-Wiza D, Zozulinska D, Banaszak A, et al. The relation between increment of postprandial glycaemia and polymorphonuclear neutrophils function in type 2 diabetes. Diabetologia. 2003; 46 (Suppl 2): A400.
18. Majchrzak A, Zozulinska D, Wierusz-Wysocka B. Evaluation of selected components in antioxidant systems of blood in patients with diabetes Ocena wybranych ukladów antyoksydacyjnych we krwi chorych na cukrzycȩ. Pol Merkur Lek. 2001; 10:150-152.
19. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004; 24: 816-823.
20. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998; 15: 539-553.
21. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet. 1999; 354: 617-621.
22. Balkau B. The DECODE study. Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe. Diabetes Metab. 2000; 26: 282-286.
23. Decode Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001; 161: 397-404.
24. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998; 21: 360-367.
25. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia. 2001; 44: 2107-2114.
26. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996; 39: 1577-1583.
27. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999; 42: 926-931.
28. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program Diabetes. 1987; 36: 689-692.
29. Wedick N, Wingard D, Barrett-Connor E. A prospective study to identify the best glycemic predictors of nonfatal coronary heart disease (CHD) and cardiovascular disease (CVD) mortality; the Rancho Bernardo study. Am J Epidemiol. 2000; 151 (Suppl): 38.
30. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor per cardiovascular disease, but not impaired fasting glucose - The Funagata diabetes study. Diabetes Care. 1999; 22: 920-924.
31. Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin. 2005; 21: 989-998.
32. de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995; 333: 1237-1241.
33. Nathan DM., Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006; 49: 1711-1721.
34. Polskie Towarzystwo Diabetologiczne. Zalecenia kliniczne dotycza̧ce postȩpowania u chorych na cukrzycȩ, 2007. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Prakt. 2007 (Suppl A).
35. 1c levels in a diabetes detection program. J Clin Endocrinol Metab. 1978; 47: 578-580.
36. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W. Postprandial plasma glucose: A good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract. 1999; 46: 23-27.
37. 1c Interrelationships in Type 2 Diabetes: Implications for treatment and monitoring of metabolic control. Diabetes Care. 2001; 24: 2023-2029.
38. 1c in Type 1 diabetes? Diabet Med. 2004; 21: 468-470.
39. Boland E, Monsod T, Delucia M, et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001; 24: 1858-1862.
40. El Kebbi IM, Ziemer DC, Cook CB, et al. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care. 2004; 27: 335-339.
41. Harris MI, Flegal KM, Cowie CC, al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 19881994. Diabetes Care. 1998; 21:518-524.
42. Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B; Steering Committee of the Swedish National Diabetes Register. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003; 26: 1270-1276.
43. Fabian W, Majkowska L, Moleda P, Stefanski A. Wyrównanie cukrzycy typu 2 u chorych leczonych przez lekarzy podstawowej opieki zdrowotnej. Diabetes control in type 2 diabetic subjects treated in primary health care. Pol Arch Med Wewn. 2006; 116: 760-765.